Bausch Health Companies (NYSE:BHC) Stock Rating Lowered by StockNews.com

StockNews.com lowered shares of Bausch Health Companies (NYSE:BHC - Free Report) from a buy rating to a hold rating in a research note released on Saturday.

Other equities analysts also recently issued research reports about the stock. Royal Bank of Canada upped their price objective on shares of Bausch Health Companies from $8.50 to $10.00 and gave the company a "sector perform" rating in a research note on Friday, May 2nd. Jefferies Financial Group reissued a "hold" rating and issued a $8.00 target price (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. One analyst has rated the stock with a sell rating and seven have given a hold rating to the company's stock. According to MarketBeat.com, Bausch Health Companies has an average rating of "Hold" and a consensus price target of $7.42.

Bausch Health Companies Price Performance

Shares of NYSE BHC traded down $0.11 during midday trading on Friday, hitting $4.67. 1,272,540 shares of the company's stock were exchanged, compared to its average volume of 2,627,510. The firm's fifty day simple moving average is $5.74 and its 200-day simple moving average is $7.07. The company has a market cap of $1.69 billion, a PE ratio of -38.91, a P/E/G ratio of 0.37 and a beta of 0.34. Bausch Health Companies has a twelve month low of $3.96 and a twelve month high of $9.85.

Bausch Health Companies (NYSE:BHC - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.44). The company had revenue of $2.56 billion during the quarter, compared to analysts' expectations of $2.51 billion. Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. Equities analysts anticipate that Bausch Health Companies will post 4.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Bausch Health Companies

A number of institutional investors and hedge funds have recently made changes to their positions in BHC. Cary Street Partners Financial LLC acquired a new position in Bausch Health Companies in the 1st quarter valued at about $27,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Bausch Health Companies in the 1st quarter valued at approximately $27,000. SBI Securities Co. Ltd. increased its holdings in shares of Bausch Health Companies by 244.2% in the first quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock valued at $27,000 after purchasing an additional 3,001 shares during the period. Mountain Hill Investment Partners Corp. purchased a new stake in shares of Bausch Health Companies during the fourth quarter worth approximately $56,000. Finally, Wealthquest Corp acquired a new stake in shares of Bausch Health Companies during the first quarter worth $58,000. 78.65% of the stock is owned by hedge funds and other institutional investors.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.